• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Serve You Rx Adds Two New Biosimilars to its Formulary

by Fred Pennic 06/05/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Serve You Rx announced today the inclusion of two newly approved biosimilars to Stelara® (ustekinumab) – Otulfi™ (ustekinumab-aauz) and Yesintek™ (ustekinumab-face) – to its Biosimilar Advantage Formulary. This move is set to deliver substantial savings for self-funded employers and health-plan sponsors while maintaining therapeutic benefits for patients with conditions like Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.

– Serve You Rx, a full-service pharmacy benefit manager (PBM), is expanding its cost-saving solutions by incorporating Otulfi™ and Yesintek™, biosimilars to the widely used specialty drug Stelara®.

Significant Cost Reduction Opportunities

“The numbers tell the story here,” stated Justin Jasniewski, CEO of Serve You Rx. “With savings of up to 96% compared to as much as $152,000 annually for Stelara, these biosimilars represent a significant opportunity for our clients to manage healthcare costs while maintaining quality care for their members.”

This initiative is a collaborative effort with Mark Cuban Cost Plus Drugs and Waltz Health, aimed at improving access to high-cost specialty medications through transparent pricing and simplified distribution channels.

Collaborative Approach to Enhance Access and Affordability

“Making biosimilars like Otulfi available through Cost Plus Drugs is another step toward breaking down barriers to access,” said Dr. Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company. “By working with Serve You Rx, we’re helping more patients and health plans avoid the inflated costs that have defined the specialty drug market for too long.”

Details of the distribution include:

  • Otulfi™: To be dispensed exclusively through Mark Cuban Cost Plus Drugs via the Waltz Health specialty pharmacy network. Members are projected to save more than 96% annually compared to Stelara®.
  • Yesintek™: Will be available through Serve You Rx’s specialty pharmacy network, powered by Waltz Health. It is expected to deliver over 90% annualized savings for plan sponsors while treating the same conditions as Stelara®.

Both medications will be supported by robust copay assistance programs to ensure patient access without imposing financial barriers.

Waltz Health offers a comprehensive solution that includes a specialty pharmacy network competing on price and service, a guided patient experience, and a flexible service model designed to balance cost and patient outcomes.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Soars in NASDAQ Debut, Signaling Digital Health IPO Rebound

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |